title: A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study.
abstract: The purpose of this study was to evaluate the effectiveness and safety of concurrent chemoradiotherapy using weekly nedaplatin for the treatment of locally advanced squamous cell carcinoma of the uterine cervix. Nedaplatin at 30 mg/m(2) was administered weekly 6 times with a concurrent external beam and intracavity radiotherapy. External beam radiation was delivered with a fraction dose of 2 Gy per day for 5 days a week during a 5-week period and intracavitary brachytherapy, of which the fraction size is 6 Gy to point A, was given once a week for a total of 4 times using a remote after-loading system. Forty-five patients were enrolled in this trial between April 2003 and December 2006. Of the 45 patients, 40 (88.9%) completed the scheduled treatment and were evaluated for efficacy and safety. Of these, 4 were stage Ib2, 12 were stage IIb, 18 were stage IIIb and 6 were stage IVa. The age distribution ranged from 27 to 79 years with a median age of 58. The 40 patients achieved an objective response, 36 (90%) a complete response and 4 (10%) a partial response. At a median follow-up of 29 months (range, 8-52), the 3-year progression-free and overall survival were 58.7% (95% confidence interval, 42-75%) and 78.0% (95% confidence interval, 56-90.0%), respectively. Acute toxicities were transient and rendered non-lethal. Of the 45 patients enrolled for the trial, only 3 (6.7%) had grade 4 leukopenia and neutropenia, respectively. Grade 3 diarrhea and nausea/ vomiting were observed in 2 (4.4%) and 1 (2.2%), respectively. These results indicate that weekly nedaplatin of 30 mg/m(2) with concurrent radiotherapy is an effective and well-tolerated regimen for advanced squamous cell carcinoma of the uterine cervix.
authors.affiliation: Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Japan. yokoyama@cc.hirosaki-u.ac.jp
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: Tadao
authors.initials: T
authors.lastname: Takano
authors.forename: Kenji
authors.initials: K
authors.lastname: Nakahara
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Shoji
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Sato
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Yamada
authors.forename: Nobuo
authors.initials: N
authors.lastname: Yaegashi
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Okamura
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Kurachi
authors.forename: Toru
authors.initials: T
authors.lastname: Sugiyama
authors.forename: Toshinobu
authors.initials: T
authors.lastname: Tanaka
authors.forename: Akira
authors.initials: A
authors.lastname: Sato
authors.forename: Toru
authors.initials: T
authors.lastname: Tase
authors.forename: Hideki
authors.initials: H
authors.lastname: Mizunuma
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005720:Gamma Rays; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin